Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma.

about

Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy.

P2860

Q55398181-57E00694-1A6A-4604-AE9E-C3ADA73E1483

P2860

Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma.

Item

http://www.wikidata.org/entity/Q46299389

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Extraordinary clinical benefit ...... etastatic lung adenocarcinoma.

@en

Extraordinary clinical benefit ...... etastatic lung adenocarcinoma.

@nl

type

Item

label

Extraordinary clinical benefit ...... etastatic lung adenocarcinoma.

@en

Extraordinary clinical benefit ...... etastatic lung adenocarcinoma.

@nl

prefLabel

Extraordinary clinical benefit ...... etastatic lung adenocarcinoma.

@en

Extraordinary clinical benefit ...... etastatic lung adenocarcinoma.

@nl

P1476

Extraordinary clinical benefit ...... metastatic lung adenocarcinoma

@en

P2093

Alexa B Schrock

http://www.w3.org/2001/XMLSchema#string

Annia Martial

http://www.w3.org/2001/XMLSchema#string

Jane J Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Emerging therapeutic agents for lung cancer

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

P2888

s40164-017-0089-y

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1186/S40164-017-0089-Y

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shuyu D Li

P577

2017-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092569214

http://www.w3.org/2001/XMLSchema#string

P698

29142786

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

adenocarcinoma

P932

5674807

http://www.w3.org/2001/XMLSchema#string

Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma.

about

P2860

P2860

Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P6179

P698

P921

P932